|
1
|
Trounson A and McDonald C: Stem Cell
Therapies in Clinical Trials: Progress and Challenges. Cell Stem
Cell. 17:11–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang Y, Chen XH, Li FG, Chen YX, Gu LQ,
Zhu JK and Li P: In vitro induction of human adipose-derived stem
cells into lymphatic endothelial-like cells. Cell Reprogram.
17:69–76. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu F, Wang X, Liang G, Lv L, Zhu Y, Sun B
and Xiao Z: Effects of epidermal growth factor and basic fibroblast
growth factor on the proliferation and osteogenic and neural
differentiation of adipose-derived stem cells. Cell Reprogram.
15:224–232. 2013.PubMed/NCBI
|
|
4
|
De Ugarte DA, Morizono K, Elbarbary A,
Alfonso Z, Zuk PA, Zhu M, Dragoo JL, Ashjian P, Thomas B, Benhaim
P, et al: Comparison of multi-lineage cells from human adipose
tissue and bone marrow. Cells Tissues Organs. 174:101–109. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ikegame Y, Yamashita K, Hayashi S, Mizuno
H, Tawada M, You F, Yamada K, Tanaka Y, Egashira Y, Nakashima S, et
al: Comparison of mesenchymal stem cells from adipose tissue and
bone marrow for ischemic stroke therapy. Cytotherapy. 13:675–685.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Locke M, Feisst V and Dunbar PR: Concise
review: Human adipose-derived stem cells: Separating promise from
clinical need. Stem Cells. 29:404–411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khan WS, Adesida AB, Tew SR, Longo UG and
Hardingham TE: Fat pad-derived mesenchymal stem cells as a
potential source for cell-based adipose tissue repair strategies.
Cell Prolif. 45:111–120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fraser JK, Wulur I, Alfonso Z and Hedrick
MH: Fat tissue: An underappreciated source of stem cells for
biotechnology. Trends Biotechnol. 24:150–154. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park IS, Rhie JW and Kim SH: A novel
three-dimensional adipose-derived stem cell cluster for vascular
regeneration in ischemic tissue. Cytotherapy. 16:508–522. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fish JE, Santoro MM, Morton SU, Yu S, Yeh
RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D:
miR-126 regulates angiogenic signaling and vascular integrity. Dev
Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang S, Aurora AB, Johnson BA, Qi X,
McAnally J, Hill JA, Richardson JA, Bassel-Duby R and Olson EN: The
endothelial-specific microRNA miR-126 governs vascular integrity
and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuhnert F, Mancuso MR, Hampton J,
Stankunas K, Asano T, Chen CZ and Kuo CJ: Attribution of vascular
phenotypes of the murine Egfl7 locus to the microRNA miR-126.
Development. 135:3989–3993. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sasahira T, Kurihara M, Bhawal UK, Ueda N,
Shimomoto T, Yamamoto K, Kirita T and Kuniyasu H: Downregulation of
miR-126 induces angiogenesis and lymphangiogenesis by activation of
VEGF-A in oral cancer. Br J Cancer. 107:700–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nowak WN, Florczyk U, Józkowicz A and
Dulak J: Role of microRNA in endothelial cells-regulation of
differentiation and angiogenesis. Postepy Biochem. 59:405–414.
2013.(In Polish). PubMed/NCBI
|
|
15
|
Yan T, Liu Y, Cui K, Hu B, Wang F and Zou
L: MicroRNA-126 regulates EPCs function: Implications for a role of
miR-126 in preeclampsia. J Cell Biochem. 114:2148–2159. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meister J and Schmidt MH: miR-126 and
miR-126*: New players in cancer. ScientificWorldJournal.
10:2090–2100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ikegame Y, Yamashita K, Hayashi S, Mizuno
H, Tawada M, You F, Yamada K, Tanaka Y, Egashira Y, Nakashima S, et
al: Comparison of mesenchymal stem cells from adiposetissue and
bonemarrow for ischemicstroke therapy. Cytotherapy. 13:675–685.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakagami H, Maeda K, Morishita R, Iguchi
S, Nishikawa T, Takami Y, Kikuchi Y, Saito Y, Tamai K, Ogihara T
and Kaneda Y: Novel autologous cell therapy in ischemic limb
disease through growth factor secretion by cultured adipose
tissue-derived stromal cells. Arterioscler Thromb Vasc Biol.
25:2542–2547. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Su SJ, Yeh YT, Su SH, Chang KL, Shyu HW,
Chen KM and Yeh H: Biochanin a promotes osteogenic but inhibits
adipogenic differentiation: Evidence with primary adipose-derived
stem cells. Evid Based Complement Alternat Med. 2013:8460392013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu Z, Yin H, Liu T, Yan W, Li Z, Chen J,
Chen H, Wang T, Jiang Z, Zhou W and Xiao J: MiR-126-5p regulates
osteoclast differentiation and bone resorption in giant cell tumor
through inhibition of MMP-13. Biochem Biophys Res Commun.
443:944–949. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
El-Kenawi AE and El-Remessy AB:
Angiogenesis inhibitors in cancer therapy: Mechanistic perspective
on classification and treatment rationales. Br J Pharmacol.
170:712–729. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu B, Peng XC, Zheng XL, Wang J and Qin
YW: MiR-126 restoration down-regulate VEGF and inhibit the growth
of lung cancer cell lines in vitro and in vivo. Lung Cancer.
66:169–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu X, Li H, Long L, Hui L, Chen H, Wang
X, Shen H and Xu W: miR-126 enhances the sensitivity of non-small
cell lung cancer cells to anticancer agents by targeting vascular
endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai).
44:519–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu
T, Bai Y, Shen Y, Yuan W, Jing Q and Qin Y: Endothelial-specific
intron-derived miR-126 is down-regulated in human breast cancer and
targets both VEGFA and PIK3R2. Mol Cell Biochem. 351:157–164. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng R, Chen X, Yu Y, Su L, Yu B, Li J,
Cai Q, Yan M, Liu B and Zhu Z: miR-126 functions as a tumour
suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010.
View Article : Google Scholar : PubMed/NCBI
|
